Talk:Fenofibrate: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk (New page: {{subpages}}) |
imported>David E. Volk (Just stick it in) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
== Synergistic use of PPARs for different subreceptors? == | |||
Both for personal use and research interest, I've been following some of the literature in the combined use of thiazolidinediones and fibrates. As you probably know, there seem to be some synergies in lowering cardiovascular risk, perhaps also with the fibrate potentiating the TZD role in decreasing insulin resistance by lowering circulating FFA. | |||
Where might such a discussion go? | |||
Howard | |||
[[User:Howard C. Berkowitz|Howard C. Berkowitz]] 23:55, 27 May 2008 (CDT) | |||
Just start a new paragraph and write about it. If you point me to some thiazolidinediones in particular I can make a chemical structure drawing for you. [[User:David E. Volk|David E. Volk]] 08:45, 28 May 2008 (CDT) | |||
Latest revision as of 07:45, 28 May 2008
Synergistic use of PPARs for different subreceptors?
Both for personal use and research interest, I've been following some of the literature in the combined use of thiazolidinediones and fibrates. As you probably know, there seem to be some synergies in lowering cardiovascular risk, perhaps also with the fibrate potentiating the TZD role in decreasing insulin resistance by lowering circulating FFA.
Where might such a discussion go?
Howard Howard C. Berkowitz 23:55, 27 May 2008 (CDT)
Just start a new paragraph and write about it. If you point me to some thiazolidinediones in particular I can make a chemical structure drawing for you. David E. Volk 08:45, 28 May 2008 (CDT)